A detailed history of Kovack Advisors, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Kovack Advisors, Inc. holds 322 shares of REGN stock, worth $225,995. This represents 0.04% of its overall portfolio holdings.

Number of Shares
322
Previous 332 3.01%
Holding current value
$225,995
Previous $348,000 2.87%
% of portfolio
0.04%
Previous 0.04%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$1024.09 - $1201.76 $10,240 - $12,017
-10 Reduced 3.01%
322 $338,000
Q4 2023

Feb 02, 2024

SELL
$775.18 - $881.7 $2,325 - $2,645
-3 Reduced 0.9%
332 $291,000
Q3 2023

Oct 19, 2023

BUY
$692.45 - $844.37 $4,154 - $5,066
6 Added 1.82%
335 $275,000
Q2 2023

Jul 21, 2023

SELL
$700.03 - $830.35 $35,701 - $42,347
-51 Reduced 13.42%
329 $236,000
Q1 2023

Apr 20, 2023

BUY
$680.49 - $826.97 $37,426 - $45,483
55 Added 16.92%
380 $312,000
Q4 2022

Feb 22, 2023

SELL
$705.89 - $766.39 $7,058 - $7,663
-10 Reduced 2.99%
325 $234,000
Q3 2022

Nov 14, 2022

SELL
$573.97 - $724.32 $458,602 - $578,731
-799 Reduced 70.46%
335 $231,000
Q2 2022

Aug 10, 2022

SELL
$548.35 - $738.84 $285,690 - $384,935
-521 Reduced 31.48%
1,134 $670,000
Q1 2022

May 16, 2022

BUY
$595.12 - $698.43 $167,823 - $196,957
282 Added 20.54%
1,655 $1.16 Million
Q4 2021

Jan 18, 2022

SELL
$543.48 - $670.97 $58,695 - $72,464
-108 Reduced 7.29%
1,373 $867,000
Q3 2021

Nov 03, 2021

BUY
$574.03 - $680.96 $623,396 - $739,522
1,086 Added 274.94%
1,481 $896,000
Q2 2021

Jul 29, 2021

BUY
$472.8 - $558.54 $186,756 - $220,623
395 New
395 $221,000
Q3 2020

Nov 02, 2020

SELL
$544.75 - $658.21 $198,833 - $240,246
-365 Closed
0 $0
Q2 2020

Jul 31, 2020

BUY
$493.32 - $643.92 $180,061 - $235,030
365 New
365 $228,000
Q2 2019

Aug 14, 2019

SELL
$299.6 - $414.82 $166,577 - $230,639
-556 Closed
0 $0
Q1 2019

May 03, 2019

BUY
$372.08 - $439.57 $206,876 - $244,400
556 New
556 $228,000
Q4 2018

Feb 06, 2019

SELL
$335.82 - $403.04 $171,604 - $205,953
-511 Closed
0 $0
Q3 2018

Oct 09, 2018

SELL
$351.14 - $408.51 $80,762 - $93,957
-230 Reduced 31.04%
511 $206,000
Q2 2018

Aug 01, 2018

SELL
$284.6 - $344.99 $72,573 - $87,972
-255 Reduced 25.6%
741 $256,000
Q1 2018

May 15, 2018

BUY
$315.82 - $393.78 $62,848 - $78,362
199 Added 24.97%
996 $343,000
Q4 2017

May 15, 2018

SELL
$358.63 - $469.95 $8,965 - $11,748
-25 Reduced 3.04%
797 $300,000
Q4 2017

Feb 01, 2018

SELL
$358.63 - $469.95 $105,795 - $138,635
-295 Reduced 26.41%
822 $309,000
Q3 2017

Aug 02, 2018

BUY
$431.38 - $504.0 $8,627 - $10,080
20 Added 1.82%
1,117 $499,000
Q2 2017

Aug 30, 2018

SELL
N/A
-1,279 Reduced 53.83%
1,097 $539,000
Q1 2017

Sep 05, 2018

BUY
N/A
1,424 Added 149.58%
2,376 $921,000
Q4 2016

Sep 10, 2018

BUY
N/A
952
952 $349,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Kovack Advisors, Inc. Portfolio

Follow Kovack Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kovack Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kovack Advisors, Inc. with notifications on news.